DelveInsight Evaluates a Robust Anaplastic Thyroid Cancer Clinical Trial Pipeline as 8+ Influential Pharma Players to Set Foot in the 7MM
The Anaplastic Thyroid Cancer Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Anaplastic Thyroid Cancer treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Anaplastic Thyroid Cancer pipeline landscape and fostering the potential growth of Anaplastic Thyroid Cancer therapeutic advancements.
Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report
- DelveInsight’s Anaplastic Thyroid Cancer pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
- The leading companies working in the Anaplastic Thyroid Cancer market include Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics Inc., Merck & Co, Iovance Biotherapeutics Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others.
- Promising Anaplastic Thyroid Cancer Pipeline Therapies in the various stages of development include HLX208, Lenvatinib, Nivolumab, Trametinib, Paclitaxel, Tremelimumab, MLN0128, AIC100 CAR T Cells, Efatutazone, PDR001, Avutometinib, Defactinib, and others.
- On January 2023, Makoto Tahara, National Cancer Center Hospital East announced a study of Phase 2 Clinical Trials for Lenvatinib and Nivolumab. This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.
- On May 2023, Memorial Sloan Kettering Cancer Center announced a study of Phase Early Phase 1 Clinical Trials for Trametinib and Paclitaxel. The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.
- On August 2023, Shanghai Henlius Biotech announced a study of Phase 1 & 2 Clinical Trials for HLX208. The purpose of this study was to assess efficacy, safety and PK in anaplastic thyroid cancer (ATC) given HLX208 (BRAF V600E inhibitor).
Request a sample and discover the recent advances in Anaplastic Thyroid Cancer Treatment Drugs @ Anaplastic Thyroid Cancer Pipeline Report
The Anaplastic Thyroid Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anaplastic Thyroid Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anaplastic Thyroid Cancer clinical trial landscape.
Anaplastic Thyroid Cancer Overview
Anaplastic thyroid cancer, or ATC, is a type of thyroid cancer. The thyroid is a gland located in the front of your neck, just below the Adam’s apple. It is responsible for sending the hormones to the rest of the body.
Find out more about Anaplastic Thyroid Cancer Treatment Drugs @ Drugs for Anaplastic Thyroid Cancer Treatment
Anaplastic Thyroid Cancer Emerging Drugs Profile
- Sapanisertib: Takeda
- HLX208: Shanghai Henlius Biotech
Anaplastic Thyroid Cancer Pipeline Therapeutics Assessment
The Anaplastic Large Cell Lymphoma pipeline report proffers an integral view of the Anaplastic Large Cell Lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Anaplastic Thyroid Cancer Pipeline Therapies @ Anaplastic Thyroid Cancer Clinical Trials Assessment
Scope of the Anaplastic Thyroid Cancer Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics Inc., Merck & Co, Iovance Biotherapeutics Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others.
- Anaplastic Thyroid Cancer Pipeline Therapies- HLX208, Lenvatinib, Nivolumab, Trametinib, Paclitaxel, Tremelimumab, MLN0128, AIC100 CAR T Cells, Efatutazone, PDR001, Avutometinib, Defactinib, and others.
Dive deep into rich insights for new drugs for Anaplastic Thyroid Cancer Treatment, Visit @ Anaplastic Thyroid Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Anaplastic Thyroid Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Anaplastic Thyroid Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Sapanisertib: Takeda
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AIC100: AffyImmune Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Anaplastic Thyroid Cancer Key Companies
- Anaplastic Thyroid Cancer Key Products
- Anaplastic Thyroid Cancer- Unmet Needs
- Anaplastic Thyroid Cancer- Market Drivers and Barriers
- Anaplastic Thyroid Cancer- Future Perspectives and Conclusion
- Anaplastic Thyroid Cancer Analyst Views
- Anaplastic Thyroid Cancer Key Companies
- Appendix
For further information on the Anaplastic Thyroid Cancer Pipeline therapeutics, reach out to Anaplastic Thyroid Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting
